Ph.D. Niro Ramachandran - 08 Jul 2025 Form 4 Insider Report for Akoya Biosciences, Inc. (AKYA)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
10 Jul 2025, 20:40:45 UTC
Prior SEC filing
25 Mar 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Niro Ramachandran, Ph.D.
Filing notes and source

Key filing fact

Ph.D. Niro Ramachandran filed Form 4 for Akoya Biosciences, Inc. (AKYA) on 10 Jul 2025.

Key facts

  • This page summarizes Ph.D. Niro Ramachandran's Form 4 filing for Akoya Biosciences, Inc. (AKYA).
  • 8 reported transactions and 4 derivative rows are listed below.
  • Accepted by SEC: 10 Jul 2025, 20:40.

Change

  • Previous filing in this sequence was filed on 25 Mar 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001857443 Primary reporting owner

Ramachandran Niro Ph.D

Relationship
Chief Business Officer
Address
C/O AKOYA BIOSCIENCES, INC., 100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH
Signature
/s/ Niro Ramachandran, Ph.D.
Signature date
10 Jul 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AKYA transaction

Common Stock

Other

Transaction value
Shares
+62,566
Change %
+24%
Price
Shares after
324,703
Date
08 Jul 2025
Ownership
Direct
Footnotes
F1, F2
AKYA transaction

Common Stock

Tax liability

Transaction value
Shares
-42,148
Change %
-13%
Price
Shares after
282,555
Date
08 Jul 2025
Ownership
Direct
Footnotes
F2
AKYA transaction

Common Stock

Other

Transaction value
Shares
-151,930
Change %
-54%
Price
Shares after
130,625
Date
08 Jul 2025
Ownership
Direct
Footnotes
F3, F4
AKYA transaction

Common Stock

Other

Transaction value
Shares
-130,625
Change %
-100%
Price
Shares after
0
Date
08 Jul 2025
Ownership
Direct
Footnotes
F3, F4, F5

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AKYA transaction Derivative

Employee Stock Option (Right to Buy)

Other

Transaction value
$0
Shares
-62,566
Change %
-100%
Price
$0.000000
Shares after
0
Date
08 Jul 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
62,566
Exercise price
$0.9087
Footnotes
F1, F2
AKYA transaction Derivative

Employee Stock Option (Right to Buy)

Other

Transaction value
$0
Shares
-45,000
Change %
-100%
Price
$0.000000
Shares after
0
Date
08 Jul 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
45,000
Exercise price
$11.88
Footnotes
F6, F7
AKYA transaction Derivative

Employee Stock Option (Right to Buy)

Other

Transaction value
$0
Shares
-45,000
Change %
-100%
Price
$0.000000
Shares after
0
Date
08 Jul 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
45,000
Exercise price
$12.30
Footnotes
F6, F7
AKYA transaction Derivative

Employee Stock Option (Right t

Other

Transaction value
$0
Shares
-70,000
Change %
-100%
Price
$0.000000
Shares after
0
Date
08 Jul 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
70,000
Exercise price
$5.35
Footnotes
F6, F7
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Ph.D. Niro Ramachandran is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 7 footnotes

Footnote F1

Cashless exercise of options pursuant to that certain Amended and Restated Agreement and Plan of Merger dated as of April 28, 2025, as amended (the "Merger Agreement"), by and among Quanterix Corporation, a Delaware corporation ("Quanterix"), Wellfleet Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Quanterix ("Merger Sub"), and Issuer. On July 8, 2025 (the "Closing Date"), Merger Sub merged with and into Issuer (the "Merger"), with Issuer surviving the Merger as a wholly owned subsidiary of Quanterix.

Footnote F2

Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price less than the value of the Per Share Merger Consideration (as defined below) was automatically cashless exercised.

Footnote F3

Disposition of shares pursuant to Merger Agreement.

Footnote F4

In connection with the terms of the Merger Agreement, each share of common stock of Issuer outstanding on the Closing Date was converted into the right to receive (a) 0.1461 of a share of common stock of Quanterix (the "Per Share Stock Consideration") and (b) $0.38 in cash, without interest (the "Per Share Cash Consideration" and together with the Per Share Stock Consideration, the "Per Share Merger Consideration"). Each of the Per Share Stock Consideration and the Per Share Cash Consideration may be adjusted pursuant to the terms of the Merger Agreement.

Footnote F5

Represents aggregate share value of Issuer restricted stock units ("RSU") unvested immediately prior to the Closing Date (each individual RSU, a "Rollover RSU"). On the Closing Date, each Rollover RSU was automatically converted into the right to receive the Per Share Merger Consideration for each share of Issuer common stock subject to such Rollover RSU upon vesting, subject to the same terms and conditions of each Rollover RSU in effect immediately prior to the effectiveness of the Merger.

Footnote F6

Disposition of options pursuant to Merger Agreement.

Footnote F7

Pursuant to the Merger Agreement, as of Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .